We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Dementia Testing by Smartphone Shows Promising Results

Dementia Testing by Smartphone Shows Promising Results

April 3, 2024

Can remote cognitive testing via smartphones yield reliable and valid data to evaluate people for a type of dementia? Findings of a study of 360 individuals spanning over four and a half years indicate the answer is yes.

This smartphone app assessment could provide dependable and scalable remote evaluations of frontotemporal lobar degeneration (FTLD), the most common form of dementia for people under age 60 and a neurodegenerative pathology that can result in speech, movement, cognition and personality shifts, study authors say.

The results of the study, published in JAMA Network Open, suggest the ease of use and dependability of the ALLFTD Mobile App — a smartphone-based platform for remote, self-administered data collection — showed moderate to excellent reliability with the participants and presents a complementary approach to traditional in-person trial designs.

View the JAMA Network Open article here.

To read the whole story, click here to subscribe.

Related Topics

Devices Research and Development

    Upcoming Events

    • 04Apr

      Managing Data and Documentation for FDA Inspections and Remote Assessments

    • 11Apr

      Integrating Regulatory Intelligence into Supplier Management

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    • 25Apr

      A Masterclass on Effective 483 Responses

    • 07May

      Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

    • 14May

      2024 Avoca Quality Consortium Summit

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • IRA Drug Prices Could Be Less Than Actual Value, Researchers Say

    • First Molecular Malaria Test to Screen Blood Donors Approved by FDA

    • Two Policy Papers Outline CDER’s Role in Assessing REMS Plans

    • Dementia Testing by Smartphone Shows Promising Results

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing